More than 60% of complement inhibitor–naive patients with acetylcholine receptor–positive generalized myasthenia gravis (MG) in diverse clinical populations had a clinically meaningful reduction in MG ...

Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...

Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was presented at the American Association of Neuromuscular & Electrodiagnostic ...

Ocular MG is a milder form of generalized MG, with lower AChR titers and less aggressive treatment needs. AChR titers above 100 nmol/L at diagnosis predict progression from ocular to generalized MG.

Now that ZILBRYSQ is approved and commercially available, the ONWARD™ program will be in place to provide further care and support for those navigating the complexities of this disease. With UCB's two ...

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG) ...

The FDA approved UCB SA's UCBJF UCBJY Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific ...

People with myasthenia gravis may need to use many different medicines to manage their symptoms. In recent years, a new group of medicines called complement inhibitors have been approved to treat this ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nicholas J.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The expanded application makes this the first available ...